Movymia^® is indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Movymia^® is also indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. Please refer to the Summary of Product Characteristics for further information. Movymia^® is administered via a reusable, multi-dosage injection device; the “Movymia^® Pen”. The pen is designed to be used for the entire duration of the treatment.

Clonmel Healthcare continues to grow and strengthen its portfolio of Biosimilar medicines. Martin Gallagher, Director of Marketing at Biosimilars Division in Clonmel Healthcare said; “Since launching this product in 2019 we remain steadfastly committed to bringing a comprehensive range of Biosimilar medicines to the market, thus offering therapeutic options to the prescribing physicians”.

A copy of the Summary of Product Characteristics is available upon request or go to www.clonmelhealthcare.ie.     Marketing authorisation holder: STADA Arzneimittel AG, Stadastrasse 2-18, 61118 Bad Vilbel, German. Marketing authorisation number: EU/1/16/1161/001-003. Medicinal product subject to medical prescription. Date last revised: January 2022.